Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Operating Leases (2023 - 2025)

CG Oncology's Operating Leases history spans 3 years, with the latest figure at $3.1 million for Q4 2025.

  • For Q4 2025, Operating Leases rose 5873.08% year-over-year to $3.1 million; the TTM value through Dec 2025 reached $3.1 million, up 5873.08%, while the annual FY2025 figure was $3.1 million, 5873.08% up from the prior year.
  • Operating Leases reached $3.1 million in Q4 2025 per CGON's latest filing, down from $3.3 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $3.3 million in Q3 2025 to a low of $52000.0 in Q4 2024.
  • Average Operating Leases over 3 years is $954555.6, with a median of $244000.0 recorded in 2023.
  • Peak YoY movement for Operating Leases: crashed 78.69% in 2024, then skyrocketed 5873.08% in 2025.
  • A 3-year view of Operating Leases shows it stood at $244000.0 in 2023, then plummeted by 78.69% to $52000.0 in 2024, then surged by 5873.08% to $3.1 million in 2025.
  • Per Business Quant, the three most recent readings for CGON's Operating Leases are $3.1 million (Q4 2025), $3.3 million (Q3 2025), and $706000.0 (Q2 2025).